Remote monitoring improves long-term in-home care

A new study from the University of California San Francisco, supported by supported by the Health Resources and Services Administration (HRSA) of HHS, shows using remote patient monitoring can improve chronic disease management.

The study focused on practices that combine electronic remote patient monitoring and telehealth to improve patient outcomes while reducing hospitalizations and costs for those needing long-term care for chronic conditions.

The study first sorted remote monitoring technology by the chronic conditions for which it was used to manage. These conditions included chronic obstructive pulmonary disease (COPD), congestive heart failure, hypertension and hyperlipidemia. Twenty healthcare providers were then interviewed on their use of technologies and data collection.

Results showed that, for all four chronic conditions, patient outcomes improved with the use of remote patient monitoring. While these results are positive, researchers emphasized that providers must be trained to not only know how to use the technology but also how to verbally assist patients, what question to ask and make accurate clinical judgments.

“Telemonitoring will never fully replace hands-on clinical care, however to fully achieve the potential of remote monitoring, programs should invest robustly in training,” concluded Aubri Kottek, the first author on the study, and colleagues. “An expanded effort to share information across remote monitoring programs would accelerate learning and enhance success. Additional research is needed to identify best practices and standards for alerts and intervention. As health care organizations face greater pressure to improve the quality of care while controlling costs, they will need to accurately determine the costs of each of the components of remote monitoring programs and assess their value.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.